Clinical Trial Update: Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies [Phase 2]

View source ↗

Summary

Phase IIa study of BRY812 as monotherapy for advanced gynecologic cancers has been announced and is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancer

Drugs mentioned

• BRY812

Snippet

Sponsor: BioRay Pharmaceutical Co., Ltd. | Conditions: Advanced Gynecological Malignancies | Phase 2 | Status: NOT_YET_RECRUITING